Institutional Review Board, Hospital for Special Surgery
August 02, 2011
The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.
For further information, see Understanding Clinical Trials.
Sherry Backus, PT, DPT, MA
Eric Bogner, MD
Frank A. Cordasco, MD, MS
Jocelyn Hafer, MA
Glenn Garrison, CPO
David Hunter, MD, PhD
Yatin Kirane, D.Orth, PhD
Andrew Kraszewski, MS
Mark Lenhoff, BS
Stephen Lyman, PhD
Lisa A. Mandl, MD, MPH
Helene Pavlov, MD, FACR
Hollis G. Potter, MD
Scott A. Rodeo, MD
Peter Torzilli, PhD
Thomas L Wickiewicz, MD
Riley J. Williams, MD
• Men and women between the ages of 40 and 80 years
• Mild to moderate knee OA
• Ability to walk independently without an assistive device
• Pregnant or nursing women
• Advanced OA in other knee
• History of replacement surgery of any lower limb joint
• Neuro-musculo-skeletal condition that interferes with walking gait (e.g. rheumatoid arthritis, psoriasis, gout, joint infection, venous or lymphatic leg stasis, peripheral vascular disease, etc.)
• Significantly compromised cardiovascular condition
• Currently taking anticoagulants and narcotic analgesics
7. Contact Information for the study:
Howard J. Hillstrom, Ph.D.